Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 64.5%

Neg 0% Neu 0% Pos 64.5%

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.